Furthermore, an oral administration of RVX208 (Apabetalone) is currently undergoing a phase one: https://clinicaltrials.gov/ct2/show/NCT03655704 (accessed on 14 May 2022) and a phase two: https://clinicaltrials.gov/ct2/show/NCT04915300 (accessed on 14 May 2022) clinical trial to investigate the efficacy and safety of targeting BRD4 in PAH therapy. This evidence concerns the gene BRD4 and pulmonary arterial hypertension.